PLRX Stock — Pliant Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Our lead program is focused on the development of treatments for solid tumors by inhibiting integrin-mediated activation of transforming growth factor-β (TGF-β).

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.77

Market cap

$47.6M

Cash

$158.1M

Enterprise value

-$110.5M

Balance sheet

Cash	$158.1M
Debt	$0.0M
Net cash	$158.1M
Enterprise value	-$110.5M
Basic shares	61.9M shares
Fully diluted shares	75.6M shares
Fully diluted market cap	$58.2M
Cash per share	$2.55
Quarterly burn	$12.8M
Cash runway	12.4 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-11.

Share structure

Common

61.9M

Pre-funded warrants

0.0M

Options

11.6M

RSUs

0.5M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.6M

FDSO

75.6M

Cap table as of 2026-06-30.

Price history

Loading PLRX daily closes…

Loading price history…

Next catalyst

PLN-101095 · Jul 13 - Aug 24 in 45 mo · Phase 1 · Advanced or Metastatic Solid Tumor

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24 in 45 mo	PLN-101095	Phase 1	Advanced or Metastatic Solid Tumor	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PLN-101095

Phase 1 · Active Modality: oral small molecule dual selective inhibitor

Target αvβ8/αvβ1 integrins

Indications

Solid tumors resistant to immune checkpoint inhibitors (ICIs) (Phase 1)
NSCLC, clear cell renal cell carcinoma, high tumor mutational burden tumors (FORTIFY Phase 1b expansion) (Phase 1)

Status note Dual selective inhibitor of αvβ8 and αvβ1 integrins. Phase 1b FORTIFY indication expansion (up to 102 patients: NSCLC, ccRCC, high TMB) enrollment continues.

bexotegrast

Phase 2 · Terminated Modality: oral small molecule dual-selective inhibitor

Target αvβ6/αvβ1 integrins

Indications

Idiopathic pulmonary fibrosis (BEACON-IPF Phase 2b) (Phase 2)
Primary sclerosing cholangitis (INTEGRIS-PSC) (Phase 2)

Status note Dual-selective inhibitor of αvβ6 and αvβ1. Development discontinued Mar 2025: BEACON-IPF Phase 2b discontinued following prespecified data review and recommendations by the independent DSMB and an outside expert panel (unadjudicated imbalance).

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PLN-101095
Lead indication	Advanced or Metastatic Solid Tumor
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06270706	Phase 1	Recruiting	Sponsor	PLRX	—	Advanced or Metastatic Solid Tumor	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Pliant Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	6,141,261	-1,871	0.32%	2026-08-14
ADAR1 Capital Management	5,509,724	+2,924,598	0.30%	2026-08-14
Ikarian Capital	1,000,000	+1,000,000	0.19%	2026-08-14
DAFNA Capital	487,000	no change	0.11%	2026-08-14
Stonepine Capital	230,538	+5,888	0.20%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PLRX — Pliant Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

PLRX — Pliant Therapeutics Inc.